^
Association details:
| Biomarker: | PMS2 mutation |
|---|---|
| Cancer: | Germ Cell Tumors |
| Drug: | AiRuiKa (camrelizumab) (PD1 inhibitor) |
| Direction: | Sensitive |
Evidence:
Source:
Title:
5193 - Case report: Long-term response to Camrelizumab in a pretreated metastatic mixed testicular germ cell tumor patient
Published date:
03/09/2022
Excerpt:
We reported a 19-year-old male patient with pretreated metastatic mixed TGCT harboring 5 variations in the BRCA2, MSH6 and PMS2 genes detected using plasma-based circulating tumor DNA (ctDNA). He obtained a durable clinical benefit from single-agent Camrelizumab (a PD-1 inhibitor), with the progression-free survival (PFS) of over 19 months and overall survival (OS) of over 6 years.
